Literature DB >> 26369963

Observed Antagonistic Effect of Linezolid on Daptomycin or Vancomycin Activity against Biofilm-Forming Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model.

Megan K Luther1, Kerry L LaPlante2.   

Abstract

Pharmacodynamic activity in antibiotic combinations of daptomycin, vancomycin, and linezolid was investigated in a 48-h in vitro pharmacodynamic model. Using human-simulated free drug concentrations, activity against clinical biofilm-forming methicillin-resistant Staphylococcus aureus isolates was evaluated. Linezolid antagonized vancomycin activity at 24 and 48 h. Linezolid antagonized daptomycin at 24 and 48 h depending on dose and strain. Adding daptomycin increased vancomycin activity at 48 h (P < 0.03). These results may be strain dependent and require further clinical investigation.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26369963      PMCID： PMC4649148          DOI： 10.1128/AAC.01604-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

Review 1.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

2.  Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin; studies including observations on an apparent antagonism between penicillin and aureomycin.

Authors:  M H LEPPER; H F DOWLING
Journal:  AMA Arch Intern Med       Date:  1951-10

3.  Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

4.  Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.

Authors:  Kerry L LaPlante; Suzanne Woodmansee
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

5.  Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.

Authors:  Lauren M Boak; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

6.  Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.

Authors:  Kerry L LaPlante; Michael J Rybak; Kimberly D Leuthner; Judy N Chin
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.

Authors:  Mark Benvenuto; David P Benziger; Sara Yankelev; Gloria Vigliani
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

9.  Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.

Authors:  Steven N Leonard; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2008-11-04       Impact factor: 5.790

10.  In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus.

Authors:  Shveta Rani Singh; Alfred E Bacon; David C Young; Kimberly A Couch
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191
View more
  3 in total

1.  Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations.

Authors:  Jordan R Smith; Juwon Yim; Seth Rice; Kyle Stamper; Razie Kebriaei; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

2.  Community-Acquired MRSA Pericarditis and Mediastinitis in a Previously Healthy Infant.

Authors:  Joselito Sanchez; Amanda Schneider; Justin T Tretter; Bo Shopsin; Yasir Al-Qaqaa; Alka Khaitan; Tanya Chadha
Journal:  J Pediatr Intensive Care       Date:  2017-10-26

3.  Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an In Vitro Pharmacodynamic Model Using Humanized Dosing Simulations.

Authors:  Jaclyn A Cusumano; Kathryn E Daffinee; Emily C Piehl; Mónica García-Solache; Charlene Desbonnet; Louis B Rice; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2022-09-26       Impact factor: 5.938
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.